Lynparza is intended for:
- for the treatment of ovarian cancer in patients carrying the BRCA mutation whom have responded to previous platinum-based chemotherapy. A test is used to determine whether the cancer you are suffering from has the BRCA mutation.
- for the treatment of metastatic breast cancer in patients with mutations in BRCA and HER2-negative, who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. If you have hormone receptor (HR)-positive disease, the recommendations are treatment with endocrine therapy.